| Acquired by | York Pharma |
| Price | $109k |
| Date | 10/08 |
| Website | celltran.com |
| Category | BioTech |
| Phone | 44 11 4222 0980 |
| info@celltran.com | |
| Employees | |
| Founded | 2000 |
| TOTAL | $7.27M |
| FUNDING TOTAL | $7.27M |
| Venture Round, 2/05 YFM Venture Finance | $470k |
| Venture Round, 8/05 Spirit Capital Partners YFM Private Equity Partnerships UK Fusion IP | $4.82M |
| Venture Round, 8/07 YFM Private Equity South Yorkshire Investment Fund Innogenetics PUK Ventures White Rose Technology Seedcorn Fund | £1M |
CellTran Limited engages in the research and development of products for the regeneration of tissue and the healing of wounds. The company offers Myskin that is used for the treatment of difficult to heal wounds; Lyphoderm, a freeze-dried lysate from cultured human keratinocytes that is formulated into a hydrophilic gel; and Ulcodress, an integrated wound care dressing that provides control of moisture, infection, and proteases within the wound area. It provides skin banking services, as well as contract manufacture services in the fields of materials fabrication and cell culture. The company was founded in 2000 and is based in Sheffield, the United Kingdom. As of October 28, 2008, CellTran Limited operates as a subsidiary of York Pharma plc.
